Multiple Myeloma Clinical Trials 2023

What are the top hospitals conducting multiple myeloma research?

Leading the way in multiple myeloma clinical trials, Memorial Sloan Kettering Cancer Center in New York has emerged as a powerhouse of research and innovation. With an impressive 12 ongoing trials and a remarkable track record of 100 all-time trials dedicated to this complex blood cancer, Memorial Sloan Kettering has been at the forefront of multiple myeloma research since recording its first trial back in 2000. Not too far behind is Massachusettsn New York has emerged as a powerhouse of research and innovation. With an impressive 12 ongoing trials and a remarkable track record of 100 all-time trials dedicated to this complex blood cancer, Memorial Sloan Kettering has been at the forefront of multiple myeloma research since recording its first trial back in 2000. Not too far behind is Massachusetts General Hospital in Boston, where researchers are currently conducting ten active multiple myeloma trials, building upon their extensive history of 88 completed studies since their inaugural trial in 1984. Another renowned institution making significant contributions is the Dana Farber Cancer Institute, also based in Boston. With nine active clinical trials for multiple myeloma and an impressive tally of 87 previously conducted studies dating back to their first recorded trial in 2001, Dana Farber continues to push boundaries for improved treatment options.

In addition to these Boston-based institutions' vital contributions stands Beth Israel Deaconess Medical Center with nine ongoing clinical tests focused on multiple myeloma while having achieved sixty-seven such investigations over several decades from initiating pioneering research into this condition since1994. Further expanding access to cutting-edge treatments is Levine Cancer Institute located Charlotte; it may have fewer active multiple myeloma trials with seven underway but certainly plays a crucial role. They have contributed significantly by conducting fifty-one previous investigations starting only ten years ago around2011.

These top hospitals not only provide hope for patients battling this challenging form of cancer but also serve as beacons of progress within the medical community. By dedicating themselves to understanding and finding breakthroughs for multiple myeloma through rigorous clinical trials, these institutions pave the way towards better outcomes and brighter futures for countless individuals affected by this disease across the nation

Which are the best cities for multiple myeloma clinical trials?

When it comes to multiple myeloma clinical trials, several cities emerge as top contenders. New York City leads the way with 53 active trials focusing on promising treatments like CC-220, Cilta-cel, and Iberdomide. Boston follows closely behind with 45 ongoing studies investigating interventions such as CC-220, bb2121, and Daratumumab. Atlanta also makes a notable contribution with 19 active trials exploring Lenalidomide, CC-220, bb2121, among others. Other cities like Chicago (17 active trials) and Basking Ridge (16 active trials) in Illinois and New Jersey respectively showcase their commitment to advancing multiple myeloma research through cutting-edge investigations into various treatment options.

Which are the top treatments for multiple myeloma being explored in clinical trials?

Exciting developments are underway in the realm of multiple myeloma treatments, with a particular focus on several key therapies currently being explored through clinical trials. Leading the pack is daratumumab, which has garnered attention with six active trials and an impressive 136 all-time multiple myeloma trials since its introduction in 2012. Another promising contender is belantamab mafodotin, currently engaged in four ongoing trials and boasting 26 all-time studies dedicated to multiple myeloma since its debut in 2018. Noteworthy contributions also come from lenalidomidee myeloma trials since its introduction in 2012. Another promising contender is belantamab mafodotin, currently engaged in four ongoing trials and boasting 26 all-time studies dedicated to multiple myeloma since its debut in 2018. Noteworthy contributions also come from lenalidomide, participating in three active trials and accumulating an astounding total of 282 all-time multiple myeloma trials dating back to 2003. Additionally, emerging treatments such as cilta-cel (two active trials) and iberdomide (two active trails) have shown promise with their recent entries into the scientific landscape for this complex disease. With each trial conducted, researchers inch closer to improving outcomes for individuals battling multiple myeloma worldwide

What are the most recent clinical trials for multiple myeloma?

Recent clinical trials for multiple myeloma offer hope and potential advancements in treatment. One trial focuses on Arm I, which combines physical therapy, cognitive education, and nutrition education as a holistic approach to managing the disease. Another study investigates CT103A in patients with relapsed or refractory multiple myeloma. Additionally, ABBV-383 Dose Expansion is being evaluated as a potential therapy option. Romosozumab is also being studied for its efficacy in treating multiple myeloma. Lastly, Isatuximab and Lenalidomidee myeloma. Additionally, ABBV-383 Dose Expansion is being evaluated as a potential therapy option. Romosozumab is also being studied for its efficacy in treating multiple myeloma. Lastly, Isatuximab and Lenalidomide Maintenance are undergoing Phase 2 trials to assess their effectiveness in maintaining remission after initial treatment. These ongoing investigations hold promise for improving outcomes and quality of life for those affected by this challenging condition.

What multiple myeloma clinical trials were recently completed?

Several clinical trials investigating potential treatments for multiple myeloma have recently been completed, demonstrating ongoing advancements in the field. These include trials such as Uproleselan sponsored by Washington University School of Medicine, mRNA-1273 sponsored by the National Cancer Institute (NCI), agenT-797 sponsored by AgenTus Therapeutics, Inc., AO-176 sponsored by Arch Oncology, MGTA-145 sponsored by Stanford University, PRT1419 sponsored by Prelude Therapeutics, Romiplostim conducted at Memorial Sloan Kettering Cancer Center, Descartes 11 led by Cartesian Therapeutics, Cyclophosphamide from Celgene and many more. These trials represent significant efforts to find innovative ways to combat multiple myeloma and provide hope for patients facing this challenging disease.